idarubicinol has been researched along with Acute Disease in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (75.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Boezeman, J; de Witte, T; Haanen, C; Linssen, P; Minderman, H; van der Lely, N; Wessels, J | 1 |
Paul, C; Sundman-Engberg, B; Tidefelt, U | 1 |
Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M | 1 |
de Witte, T; Linssen, P; Masereeuw, R; Muus, P; Raymakers, R; Smeets, M; Vierwinden, G | 1 |
1 trial(s) available for idarubicinol and Acute Disease
Article | Year |
---|---|
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Topics: Acute Disease; Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Middle Aged | 1996 |
3 other study(ies) available for idarubicinol and Acute Disease
Article | Year |
---|---|
Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state.
Topics: Acute Disease; Antineoplastic Agents; Cell Division; Daunorubicin; Doxorubicin; Granulocytes; Hematopoietic Stem Cells; Humans; Idarubicin; Leukemia, Myeloid; Macrophages; Tumor Stem Cell Assay | 1994 |
Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.
Topics: Acute Disease; Aged; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged | 1994 |
Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Daunorubicin; Female; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Prospective Studies; Recurrence | 2001 |